Nitazoxanide

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Nitazoxanide is a nitrothiazolyl-salicylamide derivative and belongs to the thiazolide class. The chemical structure is 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, and the molecular formula is C12H9N3O5S (Figure 186.1). The molecular weight is 307.28 g/mol. The benzamide structure resembles niclosamide, a drug used to treat tapeworm infections, whereas the nitrothiazolyl ring shares homology with the nitroimidazole drugs metronidazole and tinidazole (see Chapter 99, Metronidazole, and Chapter 100, Tinidazole). Nitazoxanide was first described in 1975 by Jean Francois Rossignol at the Pasteur Institute in Paris, France, and originally was developed as a veterinary anthelmintic. Initial human studies in the 1980s revealed its efficacy in treating human tapeworm infections (Rossignol and Maisonneuve, 1984). Subsequent in vitro and clinical studies have demonstrated an unusually broad antimicrobial spectrum that transcends taxonomic classes, with activity against protozoan parasites, helminths, anaerobic bacteria, mycobacteria, and viruses. A series of controlled trials conducted by Romark Laboratories established the efficacy of nitazoxanide for the treatment of giardiasis and cryptosporidiosis in immunocompetent patients, leading to approval in the United States for the treatment of Cryptosporidium species and also Giardia infections. The drug is also approved in many Latin American and Asian countries for the treatment of a range of intestinal helminths.

Original languageEnglish (US)
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Pages3162-3174
Number of pages13
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
DOIs
StatePublished - Jan 1 2017

Fingerprint

nitazoxanide
Cestode Infections
Tinidazole
Helminths
Metronidazole
Niclosamide
Pharmaceutical Preparations
Nitroimidazoles
Cryptosporidiosis
Giardiasis
Giardia
Cryptosporidium
Anthelmintics
Asian Americans
Anaerobic Bacteria
Paris
Mycobacterium
France
Parasites
Molecular Weight

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Reynoso, D., & White, A. C. (2017). Nitazoxanide. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 3162-3174). CRC Press. https://doi.org/10.1201/9781315152110

Nitazoxanide. / Reynoso, David; White, A. Clinton.

Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. p. 3162-3174.

Research output: Chapter in Book/Report/Conference proceedingChapter

Reynoso, D & White, AC 2017, Nitazoxanide. in Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, pp. 3162-3174. https://doi.org/10.1201/9781315152110
Reynoso D, White AC. Nitazoxanide. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press. 2017. p. 3162-3174 https://doi.org/10.1201/9781315152110
Reynoso, David ; White, A. Clinton. / Nitazoxanide. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. pp. 3162-3174
@inbook{06c547b368f84538ba8373f3486d06f7,
title = "Nitazoxanide",
abstract = "Nitazoxanide is a nitrothiazolyl-salicylamide derivative and belongs to the thiazolide class. The chemical structure is 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, and the molecular formula is C12H9N3O5S (Figure 186.1). The molecular weight is 307.28 g/mol. The benzamide structure resembles niclosamide, a drug used to treat tapeworm infections, whereas the nitrothiazolyl ring shares homology with the nitroimidazole drugs metronidazole and tinidazole (see Chapter 99, Metronidazole, and Chapter 100, Tinidazole). Nitazoxanide was first described in 1975 by Jean Francois Rossignol at the Pasteur Institute in Paris, France, and originally was developed as a veterinary anthelmintic. Initial human studies in the 1980s revealed its efficacy in treating human tapeworm infections (Rossignol and Maisonneuve, 1984). Subsequent in vitro and clinical studies have demonstrated an unusually broad antimicrobial spectrum that transcends taxonomic classes, with activity against protozoan parasites, helminths, anaerobic bacteria, mycobacteria, and viruses. A series of controlled trials conducted by Romark Laboratories established the efficacy of nitazoxanide for the treatment of giardiasis and cryptosporidiosis in immunocompetent patients, leading to approval in the United States for the treatment of Cryptosporidium species and also Giardia infections. The drug is also approved in many Latin American and Asian countries for the treatment of a range of intestinal helminths.",
author = "David Reynoso and White, {A. Clinton}",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/9781315152110",
language = "English (US)",
isbn = "9781498747950",
pages = "3162--3174",
booktitle = "Kucers the Use of Antibiotics",
publisher = "CRC Press",

}

TY - CHAP

T1 - Nitazoxanide

AU - Reynoso, David

AU - White, A. Clinton

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Nitazoxanide is a nitrothiazolyl-salicylamide derivative and belongs to the thiazolide class. The chemical structure is 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, and the molecular formula is C12H9N3O5S (Figure 186.1). The molecular weight is 307.28 g/mol. The benzamide structure resembles niclosamide, a drug used to treat tapeworm infections, whereas the nitrothiazolyl ring shares homology with the nitroimidazole drugs metronidazole and tinidazole (see Chapter 99, Metronidazole, and Chapter 100, Tinidazole). Nitazoxanide was first described in 1975 by Jean Francois Rossignol at the Pasteur Institute in Paris, France, and originally was developed as a veterinary anthelmintic. Initial human studies in the 1980s revealed its efficacy in treating human tapeworm infections (Rossignol and Maisonneuve, 1984). Subsequent in vitro and clinical studies have demonstrated an unusually broad antimicrobial spectrum that transcends taxonomic classes, with activity against protozoan parasites, helminths, anaerobic bacteria, mycobacteria, and viruses. A series of controlled trials conducted by Romark Laboratories established the efficacy of nitazoxanide for the treatment of giardiasis and cryptosporidiosis in immunocompetent patients, leading to approval in the United States for the treatment of Cryptosporidium species and also Giardia infections. The drug is also approved in many Latin American and Asian countries for the treatment of a range of intestinal helminths.

AB - Nitazoxanide is a nitrothiazolyl-salicylamide derivative and belongs to the thiazolide class. The chemical structure is 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, and the molecular formula is C12H9N3O5S (Figure 186.1). The molecular weight is 307.28 g/mol. The benzamide structure resembles niclosamide, a drug used to treat tapeworm infections, whereas the nitrothiazolyl ring shares homology with the nitroimidazole drugs metronidazole and tinidazole (see Chapter 99, Metronidazole, and Chapter 100, Tinidazole). Nitazoxanide was first described in 1975 by Jean Francois Rossignol at the Pasteur Institute in Paris, France, and originally was developed as a veterinary anthelmintic. Initial human studies in the 1980s revealed its efficacy in treating human tapeworm infections (Rossignol and Maisonneuve, 1984). Subsequent in vitro and clinical studies have demonstrated an unusually broad antimicrobial spectrum that transcends taxonomic classes, with activity against protozoan parasites, helminths, anaerobic bacteria, mycobacteria, and viruses. A series of controlled trials conducted by Romark Laboratories established the efficacy of nitazoxanide for the treatment of giardiasis and cryptosporidiosis in immunocompetent patients, leading to approval in the United States for the treatment of Cryptosporidium species and also Giardia infections. The drug is also approved in many Latin American and Asian countries for the treatment of a range of intestinal helminths.

UR - http://www.scopus.com/inward/record.url?scp=85056677176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056677176&partnerID=8YFLogxK

U2 - 10.1201/9781315152110

DO - 10.1201/9781315152110

M3 - Chapter

SN - 9781498747950

SP - 3162

EP - 3174

BT - Kucers the Use of Antibiotics

PB - CRC Press

ER -